In this study, cystatin M loss occurred in 9 (8%) of 117 patients with DCIS and in 99 (57%) of 175 patients with IBC, supporting previous reports [3,4,7] that cystatin M is one of many factors that are involved in the acquisition of an invasive cellular phenotype in breast cancer. This evidence concerns the gene CST6 and inflammatory breast carcinoma.